@article{b7f29f2089c04106b2e8932e3a5b4b19,
title = "Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis",
author = "Naval Daver and Kontoyiannis, {Dimitrios P.}",
note = "Funding Information: DPK has received research support from Merck, Pfizer, Astellas, and T2 Biosystems, and has received honoraria from Merck, Astellas, Gilead, Amplyx, Scynexis and Jazz Pharmaceuticals. ND has received research support and honoraria from Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Incyte, Kiromics, Otsuka, Karyopharm, and Immunogen.",
year = "2017",
month = dec,
doi = "10.1016/S1470-2045(17)30852-5",
language = "English (US)",
volume = "18",
pages = "1571--1573",
journal = "The lancet oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",
}